Floatz logo

Benserazide

Dysthymia

New York State Psychiatric InstituteSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Dysthymia cohort.

Asset / SponsorPhaseRating
Cipralex
Nova Scotia Health Authority
Phase 4BBB
MELIPRAMINE
New York State Psychiatric Institute
Phase 4BBB
Wellbutrin
Nova Scotia Health Authority
Phase 4BBB
FLUOXETINE
New York State Psychiatric Institute
Phase 4BB
CITALOPRAM
New York State Psychiatric Institute
Phase 4BB

View all 9 →

Same molecule, other indications

Benserazide is also rated in:

Parkinson DiseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
69 / 100
View asset →
Depression Not Otherwise SpecifiedDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →